The 2024 biopharma M&A landscape: An overview

It's been a couple of months since pharma’s annual JP Morgan Chase Healthcare Conference, where the mood around pharma M&A this year was optimistic, albeit with a few caveats. On today’s podcast, host Jonah Comstock is joined by Cody Powers, principal of portfolio and business development at ZS Associates, to discuss those trends and predictions and how they’re shaking out so far.